PsyMed Ventures

Alto Neuroscience is a company focused on precision psychiatry and developing personalized psychiatric treatments, leveraging the biology of individuals' brains to create effective medicines.

Ancilia Bio harnesses the natural power of CRISPR to create beneficial bacterial products with immunity against destructive viruses, focusing on the virome and its applications in therapeutics, agriculture, and industrial biotechnology.

AtaiBeckley is a biotechnology company developing new mental health treatments to transform patient outcomes. Our research is focused on developing rapid-acting, robust and durable mental health treatments for large-scale patient impact.

Drug development platform focused on neurological and psychiatric disorders.

Bexson Biomedical is developing differentiated therapies using precision-driven, scalable delivery technologies for pain and mental health. Their lead candidate, BB106, is an IND-ready subcutaneous ketamine derivative in development for Moderate/Severe Acute Pain.

Bloom Science is a biotechnology company focused on discovering, developing and commercializing live biotherapeutics to treat unmet neurological and inflammatory diseases. The company utilizes its IrisRx™ discovery platform to develop novel microbiome-based therapies targeting the gut-immune-brain axis.

Bright Minds Biosciences is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, including drug-resistant epilepsy and depression, using highly selective serotonergic agonists.

Delix Therapeutics is focused on transforming brain health through the development of neuroplastogens, a novel class of compounds aimed at treating neuropsychiatric and neurodegenerative conditions.

Humans Anonymous is an anonymous live audio platform that facilitates safe spaces for communities of people with similar life experiences to share their struggles, get advice, and support each other.

ImYoo is building a patient-enabled biodiscovery platform that conducts patient-centric immune discovery studies by enabling patients to self-collect small volumes of blood at home for high-resolution single-cell genomics assays.

Iris Medicine is an early-stage life sciences company pioneering the future of RNA therapies, specifically through their innovative small binding RNA (sbRNA) technology that selectively modulates gene expression.

Presight Capital is the international venture fund of entrepreneur Christian Angermayer, operating as a registered investment adviser that can invest across public and private markets with checks from $500K to $100M+ throughout a company's entire lifecycle from seed to post-IPO. The fund is backed by prominent hedge fund managers and billionaire angels rather than traditional institutional investors, and focuses heavily on controversial frontier science like psychedelics, brain-computer interfaces, and life extension alongside transformative infrastructure bets in undercapitalized global markets.

Digital health venture capital firm focused on companies enabling new care delivery models or more efficient therapeutic development.

Jazz is a venture capital fund built entirely around human performance that invests only in technologies optimizing human health, productivity, and well-being, with a core thesis explicitly tying advances in neuroscience and brain science to behavior change. The team includes practicing scientists, neurosurgeons, and technologists, giving them primary research insight and technical diligence depth that most generalist venture firms lack.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Women-led VC systematically backs clinically rigorous, behaviorally grounded wellbeing startups tackling stigmatized areas—alcohol use disorder, menopause, mental health—using stigma as an investing edge and insisting on consumer-grade UX.